CLEVELAND, Aug. 13, 2018 (GLOBE NEWSWIRE) — Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a Conglomerate with operations in commercial and industrial products and services, and biotechnology, today announced notable financial progress, and having launched its Biotechnology & Health Services Division with significant achievements.
The Innovest Biotech Division launched with the acquisition of a twenty percent stake in StemVax Therapeutics, and with the news that the primary technology for the StemVax brain tumor vaccine had been granted patent approval after a nine year filing process. Immediately following this news, StemVax was granted exclusive worldwide rights from Cedars-Sinai Medical Center to this patent and three other technologies it will now use in its efforts to commercialize the vaccine.
Other notable July events include:
- Winslow Asset Management, the first institutional investor in Innovest Global, filed showing that they remain long shareholder
- First half 2018 revenue growth 55.8%
- Current assets of $877,861
- Cash balance of $561,062
- Unchanged free-trading float of 11,796,710 common shares
- No convertible debts, no warrants or options outstanding
- Headcount is now 44 employees
- Stock performance up 930% on the year (as of Friday August 10th, 2018 close).
- Commercial & Industrial Division generated July monthly revenue of $351,763
- The previously announced $650K+ Fortune 500 contract for providing call center services to Byram Healthcare Division was fully implemented, team trained and operational; “The Innovest team is highly professional, does an incredible job for us at the right price, and takes our business as seriously as we do,” said Perry Bernocchi, Chief Executive Officer of Byram Healthcare. “To our customers, they are part of the Byram team, and they’ve proven we can rely on them to be a proud part of our family.”
- Advanced an acquisition initiative on a top priority target, kept others in discussion, and finalized our second half plan
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and a Biotechnology & Health Services Division.
More about StemVax Therapeutics:
StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. We seek to make a difference in patient’s lives. Bringing new beginnings to the market by developing novel therapeutics. Dr. Dwain Morris-Irvin, President of Innovest’s Biotech division is the StemVax founder and Chief Science Officer.
Cedars-Sinai Medical Center is a non-profit hospital and academic health science center located in Los Angeles, California. They employ over 2,000 physicians and are considered one of the top hospitals and research organizations in the world. Dr. Irvin previously was one of their key contributors in the areas of research that he founded StemVax to pursue.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter @innovestglobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/
